P.03/06

Atty. Docket No. 98-0967A Serial No. 09/155,076 September 17, 2004

AMENDMENTS TO THE CLAIMS:

1-12. (Cancelled)

13. (Previously presented) An isolated peptide selected from the group consisting of (a) the peptide of SEQ ID No. 1, said peptide having a calcium channel modulatory function, and (b) functional variants of the peptide of SEQ ID No. 1, wherein said functional variants (i) comprise at least 6 amino acid residues, (ii) have at least 70% homology with all of the peptide of SEQ ID No. 1 and (iii) retain said calcium channel modulatory function of the peptide of SEQ ID No.1.

14-15. (Cancelled)

16. (Previously presented) A probe consisting of the peptide of claim 13, labeled with a signal moiety, or immobilized on a solid support.

17-29. (Cancelled)

- 30. (Previously presented) The peptide as claimed in claim 13, which peptide is a fragment of acetylcholinesterase.
- 31. (Previously presented) The peptide as claimed in claim 13, which peptide has been chemically synthesized.
- 32. (Previously presented) The peptide as claimed in claim 13, which is the peptide of SEQ. ID No. 1.
- 33. (Previously presented) A method for obtaining an antibody comprising using the peptide according to any one of claims 13, 30, 31 and 32 as an antigen to obtain said antibody.

P.04/06

Atty. Docket No. 98-0967A Scrial No. 09/155,076 September 17, 2004

A method of screening comprising using the peptide according to any 34. (Withdrawn) one of claims 13, 30, 31 and 32 to screen for a compound which inhibits the activity of said peptide as a calcium channel modulator.

WENDEROTH LIND & PONACK

35. (Withdrawn) A method of identifying a compound which inhibits calcium channel modulation, said method comprising using the screening method according to claim 34 to screen for and identify said compound.

36-38. (Cancelled)